Summary
This paper presents a methodology for high-resolution plasma proteome profiling using proximity extension assay paired with next-generation sequencing, applied to characterise protein variation in healthy individuals and monitor changes in newly diagnosed type 2 diabetes patients during treatment. The work demonstrates that healthy individuals maintain distinct and stable proteome profiles, and suggests that specific protein panels may enable early disease detection and personalised prediction of therapeutic response. Although requiring validation in larger cohorts, the approach supports precision medicine applications for health monitoring and disease stratification.
UK applicability
The methodology and findings are potentially applicable to UK clinical and research settings, particularly for development of precision diagnostic tools in diabetes screening and monitoring. However, the generalisability and clinical utility would require validation in UK population cohorts to account for potential differences in genetic background, lifestyle and healthcare contexts.
Key measures
Plasma protein profiles (proteome composition), inter-individual and intra-individual variability, genetic influence on plasma protein levels, response to metformin intervention in newly diagnosed type 2 diabetes patients
Outcomes reported
The study developed and validated a plasma proteome profiling approach using proximity extension assay combined with next-generation sequencing to characterise protein variability in healthy individuals and patients with type 2 diabetes. The analysis identified a panel of proteins that may be useful for early diagnosis of diabetes and stratification of patient response to metformin treatment.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.